{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:42:19Z","timestamp":1794559339335,"version":"4.9.1"},"reference-count":127,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The coexistence of psoriasis with autoimmune bullous diseases (AIBDs), particularly bullous pemphigoid (BP), has been documented in case reports and series, as well as in epidemiological studies. The onset of psoriasis precedes that of BP in the majority of cases. Patients with concomitant BP and psoriasis are generally younger at the onset of BP and present with fewer erosions and blisters as compared with patients suffering from isolated BP. Intriguingly, it has been speculated that some BP cases with comorbid psoriasis can actually correspond to anti-laminin gamma-1 pemphigoid, a rare form that was recently recognized as a distinct entity and which can mimic BP and\/or other subepidermal AIBDs. The pathomechanisms underlying the BP\u2013psoriasis association have not yet been identified, although several hypotheses have been proposed. The most credited among such hypotheses involves the so-called \u201cepitope spreading\u201d phenomenon, with tissue injury secondary to a primary inflammatory process (i.e., psoriasis) leading to the exposure of sequestered antigens evoking a secondary autoimmune disease (i.e., bullous pemphigoid). This narrative review aims to give a brief overview of the association between psoriasis and BP, examining epidemiological, clinical, and immunopathological features, the pathomechanisms underlying this association, the treatments for psoriasis incriminated as potential triggers of BP, and the therapeutic management of patients with psoriasis and BP.<\/jats:p>","DOI":"10.3390\/jcm12010328","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T03:00:59Z","timestamp":1672628459000},"page":"328","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The Intriguing Links between Psoriasis and Bullous Pemphigoid"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-849X","authenticated-orcid":false,"given":"Carlo Alberto","family":"Maronese","sequence":"first","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Cassano","sequence":"additional","affiliation":[{"name":"Dermatology Private Practice, 76121 Barletta, Italy"},{"name":"Dermatology Private Practice, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-958X","authenticated-orcid":false,"given":"Giovanni","family":"Genovese","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Unit of Dermatology, University of Bari Aldo Moro, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Dermatology Private Practice, 76121 Barletta, Italy"},{"name":"Dermatology Private Practice, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.clindermatol.2007.08.003","article-title":"The clinical spectrum of psoriasis","volume":"25","author":"Naldi","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3892\/etm.2021.10972","article-title":"Bullous pemphigoid: An immune disorder related to aging (Review)","volume":"23","author":"Deotto","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clindermatol.2011.03.005","article-title":"Bullous pemphigoid: From the clinic to the bench","volume":"30","author":"Zambruno","year":"2012","journal-title":"Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2012.09.012","article-title":"Missing the target: Characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay","volume":"68","author":"Fairley","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaad.2015.03.016","article-title":"Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases","volume":"73","author":"Ohata","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fmed.2018.00222","article-title":"Interaction of Psoriasis and Bullous Diseases","volume":"5","author":"Dainichi","year":"2018","journal-title":"Front. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Genovese, G., Moltrasio, C., Cassano, N., Maronese, C.A., Vena, G.A., and Marzano, A.V. (2021). Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121746"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/1346-8138.14902","article-title":"Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan","volume":"46","author":"Ho","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/247553031600100404","article-title":"A Systematic Review of Concomitant Bullous Pemphigoid and Psoriasis","volume":"1","author":"Donnelly","year":"2016","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajd.12899","article-title":"Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies","volume":"60","author":"Phan","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fmed.2020.00511","article-title":"The bidirectional association between bullous pemphigoid and psoriasis: A population-based cohort study","volume":"7","author":"Kridin","year":"2020","journal-title":"Front. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2017.02.057","article-title":"Association between bullous pemphigoid and psoriasis: A case-control study","volume":"77","author":"Kridin","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/jdv.17013","article-title":"Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies","volume":"35","author":"Schmidt","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0190-9622(08)80749-9","article-title":"Bullous pemphigoid and severe erythrodermic psoriasis: Combined low-dose treatment with cyclosporine and systemic steroids","volume":"27","author":"Bianchi","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2147\/CCID.S374556","article-title":"Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report","volume":"15","author":"Chen","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_18","first-page":"537","article-title":"Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine","volume":"9","author":"Roeder","year":"1999","journal-title":"Eur. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1746-1596-9-102","article-title":"Erythrodermic psoriasis with bullous pemphigoid: Combination treatment with methotrexate and compound glycyrrhizin","volume":"9","author":"Si","year":"2014","journal-title":"Diagn. Pathol."},{"key":"ref_20","first-page":"23","article-title":"Photoletter to the editor: Psoriatic erythroderma associated with bullous pemphigoid: Clinical appearance and histopathology","volume":"9","year":"2015","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2007.08333.x","article-title":"Pemphigoid nodularis associated with psoriatic erythroderma: Successful treatment with suplatast tosilate","volume":"158","author":"Teraki","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000435912","article-title":"Pemphigoid Diseases as a Sign of Active Psoriasis: A Case Report and Brief Review","volume":"231","author":"Iskandarli","year":"2015","journal-title":"Dermatology"},{"key":"ref_23","first-page":"283","article-title":"A case of bullous pemphigoid limited to psoriatic plaques","volume":"70","author":"Kobayashi","year":"2002","journal-title":"Cutis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdcr.2021.08.025","article-title":"Neutrophil-rich, noncollagenous 16A domain-negative bullous pemphigoid associated with psoriasis","volume":"16","author":"Sussman","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_25","first-page":"105","article-title":"Bullous pemphigoid associated with psoriasis showing marked neutrophilic infiltrates","volume":"19","author":"Inamura","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2230.1991.tb00408.x","article-title":"Bullous pemphigoid occurring in psoriatic plaques in association with Hashimoto\u2019s thyroiditis","volume":"16","author":"Smith","year":"1991","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_27","first-page":"E19","article-title":"Development of bullous pemphigoid in a patient with psoriasis and metabolic syndrome","volume":"98","author":"Lesniewska","year":"2016","journal-title":"Cutis"},{"key":"ref_28","first-page":"62","article-title":"Bullous pemphigoid associated with psoriasis, breast cancer and Parkinson\u2019s disease","volume":"40","author":"Stoica","year":"2014","journal-title":"Curr. Health Sci. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1046\/j.1468-3083.2002.00570_12.x","article-title":"Coexistence of psoriasis vulgaris, bullous pemphigoid and vitiligo: A case report","volume":"16","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1111\/ijd.12349","article-title":"Coexistence of psoriasis vulgaris and vitiligo with bullous pemphigoid: A case report","volume":"53","author":"Jankowski","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5070\/D328257409","article-title":"Psoriasis, sarcoidosis, and bullous pemphigoid: More than a coincidence in a single patient?","volume":"28","author":"Escalas","year":"2022","journal-title":"Dermatol. Online J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/1346-8138.13170","article-title":"Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia","volume":"43","author":"Maki","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fimmu.2019.02466","article-title":"Anti-p200 Pemphigoid: A Systematic Review","volume":"10","author":"Kridin","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000330330","article-title":"Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: Modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response","volume":"223","author":"Quaglino","year":"2011","journal-title":"Dermatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: From Pathogenesis to Targeted Therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjd.19380","article-title":"Role of regulatory T cells in psoriasis pathogenesis and treatment","volume":"184","author":"Nussbaum","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kanda, N., Hoashi, T., and Saeki, H. (2021). The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173880"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cei.13370","article-title":"Evidence for a role of autoinflammation in early-phase psoriasis","volume":"198","author":"Fanoni","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Honma, M., and Nozaki, H. (2021). Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153199"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Singh, R., Koppu, S., Perche, P.O., and Feldman, S.R. (2021). The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312793"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/PTT.S101232","article-title":"Erythrodermic psoriasis: Pathophysiology and current treatment perspectives","volume":"6","author":"Singh","year":"2016","journal-title":"Psoriasis Targets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tsai, Y.C., and Tsai, T.F. (2022). Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105518"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.jid.2016.07.008","article-title":"IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis","volume":"136","author":"Xing","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1586\/eci.12.94","article-title":"Psoriasis and susceptibility to other autoimmune diseases: An outline for the clinician","volume":"9","author":"Ali","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imm.12891","article-title":"Autoimmunity and autoimmune co-morbidities in psoriasis","volume":"154","author":"Furue","year":"2018","journal-title":"Immunology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e12945","DOI":"10.1111\/sji.12945","article-title":"Current knowledge on autoantigens and autoantibodies in psoriasis","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/1027-8117.357999","article-title":"Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy","volume":"40","author":"Lai","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102661","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_51","first-page":"411","article-title":"Autoimmunity in bullous pemphigoid","volume":"144","author":"Wong","year":"2009","journal-title":"G Ital. Dermatol Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: Eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_53","first-page":"123","article-title":"Cytokines and bullous pemphigoid","volume":"10","author":"Ameglio","year":"1999","journal-title":"Eur. Cytokine Netw."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/exd.14209","article-title":"Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease","volume":"29","author":"Margaroli","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/07853890.2020.1742367","article-title":"Factors associated with the activity and severity of bullous pemphigoid: A review","volume":"52","author":"Liu","year":"2020","journal-title":"Ann. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Vallerand","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Giustiniani","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3389\/fimmu.2019.01972","article-title":"IL-23\/IL-17 Axis Activates IL-1\u03b2-Associated Inflammasome in Macrophages and Generates an Auto-Inflammatory Response in a Subgroup of Patients With Bullous Pemphigoid","volume":"10","author":"Muller","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fimmu.2019.00701","article-title":"NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay","volume":"10","author":"Giusti","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/dermatopathology9010010","article-title":"Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation","volume":"9","author":"Niebel","year":"2022","journal-title":"Dermatopathology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1365-4632.2006.02861.x","article-title":"Concomitant psoriasis and bullous pemphigoid: Coincidence or pathogenic relationship?","volume":"45","author":"Wilczek","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope spreading: Lessons from autoimmune skin diseases","volume":"110","author":"Chan","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF00371944","article-title":"Basement membrane zone as a target for human neutrophil elastase in psoriasis","volume":"282","author":"Glinski","year":"1990","journal-title":"Arch. Dermatol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000090385","article-title":"Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid","volume":"139","author":"Niimi","year":"2006","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/exd.14267","article-title":"Could basement membrane alterations, resembling micro-wounds at the dermo-epidermal junction in psoriatic non-lesional skin, make the skin susceptible to lesion formation?","volume":"30","author":"Flink","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5114\/ada.2021.108926","article-title":"Significance of interleukin-31 (IL-31) gene polymorphisms and IL-31 serum level in psoriasis in correlation with pruritus","volume":"38","author":"Nedoszytko","year":"2021","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1046\/j.1365-2133.1996.d01-1072.x","article-title":"Acquired subepidermal bullous diseases associated with psoriasis: A clinical, immunopathological and immunogenetic study","volume":"135","author":"Kirtschig","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/1346-8138.13031","article-title":"Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehen.nsive review of the published work","volume":"43","author":"Chiorean","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_72","first-page":"214","article-title":"PUVA-induced Bullous Pemphigoid in Psoriasis","volume":"24","year":"2016","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1468-3083.2006.01966.x","article-title":"Th2 cell fluctuation in association with reciprocal occurrence of bullous pemphigoid and psoriasis vulgaris","volume":"21","author":"Sugita","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A Systematic Review of Drug-Induced Pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2020.12.001","article-title":"A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal","volume":"8","author":"Svigos","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: A review of the literature","volume":"9","author":"Stavropoulos","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ijd.14686","article-title":"Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: A systematic review","volume":"59","author":"Gibson","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1111\/1346-8138.15770","article-title":"Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa","volume":"48","author":"Sugaya","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/idoj.IDOJ_53_19","article-title":"Simultaneous Bullous Pemphigoid and Vitiligo Associated with Adalimumab Therapy in a Patient with Psoriasis Vulgaris","volume":"11","author":"Bonifaz","year":"2020","journal-title":"Indian Dermatol. Online J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1346-8138.2012.01659.x","article-title":"Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept","volume":"40","author":"Nin","year":"2013","journal-title":"J. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2007.02603.x","article-title":"A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy","volume":"33","author":"Saraceno","year":"2008","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1684\/ejd.2010.0970","article-title":"Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept","volume":"20","author":"Cusano","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jaad.2005.10.055","article-title":"Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept","volume":"54","author":"Yamauchi","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.12163","article-title":"A successful treatment with ustekinumab in a case of antilaminin-c1 pemphigoid associated with psoriasis","volume":"168","author":"Majima","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/jdv.14002","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaad.2020.12.056","article-title":"Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review","volume":"87","author":"Lytvyn","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Moro, F., Fania, L., Sinagra, J.L.M., Salemme, A., and Di Zenzo, G. (2020). Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 10.","DOI":"10.3390\/biom10101432"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"96","DOI":"10.31138\/mjr.32.2.96","article-title":"Biologic Therapies and Autoimmune Phenomena","volume":"32","author":"Drosos","year":"2021","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: A systematic review","volume":"33","author":"Steinhoff","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1111\/1346-8138.13909","article-title":"Development of bullous pemphigoid during secukinumab treatment for psoriasis","volume":"44","author":"Ho","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e15207","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Fukada, N., Suzuki, T., Aoyama, K., Kinjo, A., Yamazaki, K., and Sato, T. (2022). Bullous pemphigoid during the treatment of psoriasis vulgaris with risankizumab. J. Dermatol.","DOI":"10.1111\/1346-8138.16534"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102799","DOI":"10.1016\/j.amsu.2021.102799","article-title":"A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions","volume":"70","author":"Khalid","year":"2021","journal-title":"Ann. Med. Surg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1684\/ejd.2021.4056","article-title":"Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-\u03b1 therapy","volume":"31","author":"Karamanakos","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_97","first-page":"5450863","article-title":"Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab","volume":"2019","author":"Alahmari","year":"2019","journal-title":"Case Rep. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Miyagawa, F. (2022). Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071485"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/cia2.12126","article-title":"Doxycycline as an initial treatment of bullous pemphigoid in Japanese patients","volume":"3","author":"Kimura","year":"2020","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-4632.2010.04570.x","article-title":"The role of drugs in the induction and\/or exacerbation of psoriasis","volume":"49","author":"Basavaraj","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40257-022-00719-7","article-title":"Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review","volume":"23","author":"Hsieh","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jamadermatol.2020.4219","article-title":"Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients with a History of Psoriasis","volume":"157","author":"Gregoire","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: A systematic review","volume":"61","author":"Vincken","year":"2022","journal-title":"Rheumatology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/abd1806-4841.20198032","article-title":"Bullous pemphigoid associated with psoriasis: A good response to methotrexate","volume":"94","author":"Vargas","year":"2019","journal-title":"An. Bras. De Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/2229-5178.96707","article-title":"Coexistence of psoriasis with bullous pemphigoid","volume":"3","author":"Rao","year":"2012","journal-title":"Indian Dermatol. Online J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/15569527.2012.667030","article-title":"Coexistence of psoriasis and bullous pemphigoid: Remission with low-dose methotrexate","volume":"32","author":"Gunay","year":"2013","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_107","first-page":"124","article-title":"Concurrence of bullous pemphigoid and psoriasis: A case report","volume":"10","author":"Suwarsa","year":"2018","journal-title":"Serb. J. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000207792","article-title":"Bullous pemphigoid occurring during efalizumab treatment for psoriasis: A paradoxical auto-immune reaction?","volume":"219","author":"Guillot","year":"2009","journal-title":"Dermatology"},{"key":"ref_109","first-page":"619","article-title":"Coexistence of psoriasis and pemphigoid\u2014Only a coincidence?","volume":"18","author":"Lazarczyk","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(89)80147-1","article-title":"Bullous pemphigoid in psoriatic lesions","volume":"20","author":"Hisler","year":"1989","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/00015550510035677","article-title":"Bullous pemphigoid on psoriasis lesions after UVA radiation","volume":"85","author":"Washio","year":"2005","journal-title":"Acta Derm.-Venereol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0190-9622(98)70414-1","article-title":"Psoriasis and bullous pemphigoid treated with azathioprine","volume":"39","author":"Primka","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0190-9622(08)80058-8","article-title":"Bullous pemphigoid and psoriasis: Treatment with cyclosporine","volume":"24","author":"Boixeda","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1751-7125.2008.07318.x","article-title":"Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy","volume":"7","author":"Rallis","year":"2008","journal-title":"SKINmed Dermatol. Clin."},{"key":"ref_115","first-page":"32","article-title":"Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature","volume":"53","author":"Vural","year":"2019","journal-title":"TURKDERM-Turk. Arch. Dermatol. Venereol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2009.02.031","article-title":"Efalizumab-induced bullous pemphigoid","volume":"62","author":"Duong","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/1346-8138.16189","article-title":"Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis","volume":"49","author":"Lu","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Gu, Y., Xia, D., Zhou, X., and Li, W. (2022). Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid. J. Dermatol.","DOI":"10.1111\/1346-8138.16559"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1684\/ejd.2016.2888","article-title":"Bullous pemphigoid during ustekinumab therapy in a psoriatic patient","volume":"27","author":"Onsun","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ejhpharm-2018-001849","article-title":"Bullous pemphigoid induced by ustekinumab: A case report","volume":"28","author":"Marin","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2133.1985.tb02079.x","article-title":"Evidence of an association between bullous pemphigoid and psoriasis","volume":"113","author":"Grattan","year":"1985","journal-title":"Br. J. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2340\/00015555-1619","article-title":"Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate","volume":"94","author":"Wang","year":"2014","journal-title":"Acta Derm.-Venereol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: A case report","volume":"63","author":"Yun","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/idoj.IDOJ_416_18","article-title":"Epitope Spreading Phenomenon: A Case Report","volume":"10","author":"Krishnaswamy","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jdcr.2020.03.001","article-title":"Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid","volume":"6","author":"Tabata","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:17Z","timestamp":1760147357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010328"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010328","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]}}}